Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from Pomeranian Medical University broadens understanding of breast cancer
February 19th, 2009
According to a study from Szczecin, Poland, "To investigate the relationship between CHEK2 mutation status and estrogen receptor (ER) status in unselected cases of early-onset breast cancer from Poland, we screened 4441 women diagnosed with breast cancer younger than 51 years and 7217 controls for three inherited mutations in CHEK2 (1100delC, IVS2+1G > A, del5395). ER status was compared between CHEK2-positive and CHEK2-negative breast cancer cases." "A truncating mutation in CHEK2 was seen in 140 of 4441 cases and in 70 of 7217 controls [odds ratio (OR) = 3.3; 95% CI = 2.5-4.4; p< 0.0001]. ER status was available for 92 of 140 mutation carriers and for 3001 of...
Source: Women's Health Weekly (2009-02-19)
|
